Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Genus tumbles after warning on full-year profits

(Sharecast News) - Genus shares tumbled on Thursday as the animal genetics company warned on full-year profits. In a first-half trading update, the company said it had performed "resiliently" in challenging market conditions. It expects to report revenue of £334m and adjusted pre-tax profit of £29m, in line with expectations.

The group said that excluding China, PIC - its global porcine genetics business - performed "robustly", with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency.

Genus said China continues to be a challenging porcine market, but that its "enhanced commercial focus" has resulted in winning new royalty customers in the period which will have a positive impact in fiscal year 2025 and beyond.

The company said its bovine genetics business, ABS, saw volumes fall 6% in challenging markets. There was a particular hit to demand for dairy genetics in China due to a double-digit decline in the dairy herd.

Genus said that assuming present market conditions persist for the balance of the fiscal year, fiscal year 2024 adjusted pre-tax profit is set to be "not less than" £58m in actual currency. This is down from £71.5m a year earlier.

Deutsche Numis said this compares with its current forecast of £72.8m

As far as its PRRS Resistant Pig (PRP) programme is concerned, Genus said recent engagement with the US Food and Drug Administration has shifted to the post-approval compliance procedures.

"This has clarified the data submissions and monitoring that will be required on an ongoing basis post PRP approval.

"Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025."

At 0905 GMT, the shares were down 27% at 1,555.84p.

Share this article

Related Sharecast Articles

Frontier IP appoints new finance chief
(Sharecast News) - Intellectual property commercialisation specialist Frontier IP announced the appointment of Jo Stent as its new chief financial officer on Friday, effective from 22 April.
Directa Plus asphalt technology laid at Imola Circuit
(Sharecast News) - Graphene nanoplatelet specialist Directa Plus announced on Friday that 'GiPave', an asphalt solution incorporating graphene and recycled plastics, was being installed at the Imola Circuit ahead of the Emilia-Romagna Grand Prix in May.
Huddled Group buys Food Circle for £0.3m
(Sharecast News) - E-commerce investor Huddled Group announced the acquisition of online retailer Food Circle Supermarket on Friday, for total consideration of up to £0.3m.
Bens Creek shares fall as it moves mine into care and maintenance
(Sharecast News) - Shares in North American metallurgical coal miner Bens Creek were sliding on Friday afternoon, after the company issued an update on its operations and working capital position, confirming that its West Virginia mine was moving into care and maintenance.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.